Companies · Biotechnology

Orion Biotechnology Canada Ltd.

OTTAWA, ONTARIO · Biotechnology

Diligence memoA one-page analyst read on Orion Biotechnology Canada Ltd. — recommendation, valuation, rhythm, risks.
$11.2M
Total raised · real
3
Rounds
0.1×
Latest step-up
Top 43%
Sector rank · raised
Series A
Latest stage · inferred · Mon Jul 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Orion Biotechnology Canada Ltd. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.09× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Quiet
  • Last raise 24 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Orion Biotechnology Canada Ltd. is one of 4293 Biotechnology companies tracked from OTTAWA, ONTARIO. By capital raised it ranks mid-pack (ahead of 58% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

biotech

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
5
Investors (latest)
2024-07-08
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2020-09-24 Raised $605K (real) Modeled valuation $29M (est)$605K$29MPre-Seed2020Series A · 2021-05-28 Raised $9.9M (real) Modeled valuation $231M (est)$9.9M$231MSeries A2021Series A · 2021-05-28 Raised $5.4M (real) Modeled valuation $127M (est)$5.4M$127MSeries A2021Series A · 2021-05-28 Raised $5.4M (real) Modeled valuation $127M (est)$5.4M$127MSeries A2021Series A · 2024-07-08 Raised $6.8M (real) Modeled valuation $35M (est)$6.8M$35MSeries A2024Series A · 2024-07-08 Raised $743K (real) Modeled valuation $3.9M (est)$743K$3.9MSeries A2024+$9.9M+$5.4M+$5.4M+$6.8M+$743KCumulative $29M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$605K · 2020
Series A$9.9M · 2021no Seed on file
Series A extension$5.4M · 2021
Series A extension$5.4M · 2021
Series A extension$6.8M · 2024
Series A extension$743K · 2024

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$3.9M
Base estimate est.
$811K
Conservative case
$8.3M
Upside case
$3.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $28.9M · 2020-09-242020Series A · modeled $231.1M · 2021-05-28Series A · modeled $127.0M · 2021-05-28Series A · modeled $127.0M · 2021-05-28Series A · modeled $35.4M · 2024-07-08Series A · modeled $3.9M · 2024-07-082024
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
2.0 yr
Elapsed time used
2.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$3.0M/yr
Capital velocity
5.8 yr
On record since
2020
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.6× above median
This company$11.2M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$743K
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$3.9M
Sector median$64.2M

Raised more than 58% of sector peers (real $). Modeled value above 8% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #286 of 303.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $184.0M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)Orion Biotechnology Canada Ltd. (this company) Raised $11.2M · modeled $3.9M (est)Orion Biotechnology Canada Ltd.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc.Series A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
Orion Biotechnology Canada Ltd. this companySeries A$11.2M$3.9M0.09×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$605K2020-09-24$3.4M$28.9M90%
Series A$9.9M2021-05-28$45.0M$231.1M90%
Series A$5.4M2021-05-28$24.7M$127.0M90%
Series A$5.4M2021-05-28$24.7M$127.0M90%
Series A$6.8M2024-07-08$31.0M$35.4M90%
Series A$743K2024-07-08$3.4M$3.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$605K2020-09-24
    • First recorded raise — entered as Pre-Seed.
    • 11 investors on this round.
  2. Series A$9.9M2021-05-28
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 16.3× larger than the prior — scaling up.
    • 114 investors on this round.
  3. Series A$5.4M2021-05-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 142 investors on this round.
  4. Series A$5.4M2021-05-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 142 investors on this round.
  5. Series A$6.8M2024-07-08
    • Raised again after 37 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 34 investors on this round.
  6. Series A$743K2024-07-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 9.2× smaller than the prior — bridge or down round.
    • 5 investors on this round.
Intelligence
2025 ~Q2
Modeled next raise · ~9mo cadence
$743K
Modeled next size est.range $743K$1.2M
0.1×
Last step-up
$3.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Praveen Tyle4 other2024-07
Bradford Smith1 other2024-07
Jason Burke1 other2024-07
Katie Hewitt1 other2024-07
Lonnel Coats1 other2024-07
Theresa Firestone1 other2021-05
Anatole Sheila Klepatsky2021-05
Anatolii Klepatsky2024-07
Anatolii Klepatskyi2021-05
Anatolii Sheila Klepatskyi2020-09
Dmytro Sheila Martynenko2020-09
Jason Sheila Burke2020-09
Jason William Burke2021-05
Jean Forcione2024-07
Jean William Forcione2021-05
John Jussup2024-07
John Sheila Jussup2020-09
John William Jussup2021-05
Mark Groper2021-05
Mark Hecht2021-05
Mark Sheila Groper2020-09
Rudolf Bom2020-09
Theresa Sheila Firestone2020-09
Thomas Sheila Hecht2020-09
Registry & provenance

Orion Biotechnology Canada Ltd. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1827388
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Rodeo Therapeutics CorpBiotechnologySeries A$14.3M$323.6Mnetwork1 shared operator · same sector · same stage
Modifi Biosciences, Inc.BiotechnologySeries A$11.5M$4.9Msame sector · same stage
TellBio, Inc.BiotechnologySeries A$11.0M$4.8Msame sector · same stage
Hamilton Thorne Ltd.BiotechnologySeries A$11.5M$5.4Msame sector · same stage
Biotricity Inc.BiotechnologySeries A$10.6M$6.0Msame sector · same stage
Genialis, Inc.BiotechnologySeries A$12.1M$1.8Msame sector · same stage
Cba Pharma IncBiotechnologySeries A$10.0M$3.6Msame sector · same stage
GelMEDIX, Inc.BiotechnologySeries A$9.9M$1.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Orionis Biosciences LLCBiotechnologySeries B$782.6M91%
Redwood Scientific Technologies, Inc.BiotechnologySeed$10.5M84%
Constellation Pharmaceuticals IncBiotechnologySeries C$2.7B84%
Orion Pharma
Australian company.
Pharma84%
Orion Nutraceuticals Inc.OtherPre-Seed$2.5M83%
BirchBioMed Inc.BiotechnologySeries A$571K83%
Spruce Biosciences, Inc.BiotechnologySeries C$274.5M83%
Cyrus Biotechnology, Inc.BiotechSeries B$5.2M83%
Frequently asked
How much funding has Orion Biotechnology Canada Ltd. raised?
Orion Biotechnology Canada Ltd. has raised approximately $11.2M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Orion Biotechnology Canada Ltd.'s estimated valuation?
Provath's modeled valuation for Orion Biotechnology Canada Ltd. is approximately $3.9M (modeled range $811K–$8.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Orion Biotechnology Canada Ltd. at?
Orion Biotechnology Canada Ltd.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Jul 08.
What does Orion Biotechnology Canada Ltd. do and where is it based?
Orion Biotechnology Canada Ltd. operates in the Biotechnology sector, based in OTTAWA, ONTARIO.
Explore related

See where Orion Biotechnology Canada Ltd. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Orion Biotechnology Canada Ltd., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.